Exhaled nitric oxide is not increased in pulmonary sarcoidosis.

Abstract

BACKGROUND:

Fractional exhaled nitric oxide (FeNO) is a non-invasive biomarker of airway inflammation and nitrosative stress. Previous studies have suggested a possible role of FeNO in the management of patients with pulmonary sarcoidosis, but published data are discordant.

OBJECTIVES:

To assess the clinical usefulness of FeNO and alveolar concentration of NO (CalvNO) in sarcoidosis.

METHODS:

We measured FeNO50-100-150 and CalvNO in 31 patients with pulmonary sarcoidosis, 32 patients affected by idiopathic pulmonary fibrosis (IPF) and 30 healthy controls.

RESULTS:

Sarcoidosis group reported FeNO50-100-150 and CalvNO levels comparable to healthy controls, while IPF patients showed significantly higher values of FeNO50-100-150 and CalvNO than sarcoidosis (all p<0.05) and controls groups (all p<0.05).

CONCLUSION:

Exhaled nitric oxide is not a useful biomarker in the management of patients affected by pulmonary sarcoidosis.

• Authors: Paolo Cameli, Elena Barbagli, Paola Rottoli
• Journal: Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG (Sarcoidosis Vasc Diffuse Lung Dis) Vol. 33 Issue 1 Pg. 39-40 (Mar 29 2016) ISSN: 2532-179X [Electronic] Italy
• PMID: 27055834 (Publication Type: Journal Article)

Chemical References

• Biomarkers
• Nitric Oxide

Topics

• Biomarkers (analysis)
• Breath Tests
• Exhalation
• Humans
• Middle Aged
• Nitric Oxide (analysis)
• Sarcoidosis, Pulmonary (metabolism)